

What is claimed is:

1. A pharmaceutical composition, comprising a pharmaceutically acceptable excipient and a combination of a recombinant human 2Ig-B7-H3 protein encoding gene with a wild-type 2Ig-B7-H3 protein encoding gene, wherein the recombinant human 2Ig-B7-H3 protein encoding gene comprises the nucleotide sequence shown in SEQ ID NO: 1 and the wild-type 2Ig-B7-H3 protein encoding gene comprises the nucleotide sequence shown in SEQ ID NO: 2.

2. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is an injection solution.

3. The pharmaceutical composition of claim 1, wherein the recombinant human 2Ig-B7-H3 protein encoding gene and the wild-type 2Ig-B7-H3 protein encoding gene are carried by a vector, respectively.

4. The pharmaceutical composition of claim 3, wherein the vector is expressed in a host cell.

5. The pharmaceutical composition of claim 3, wherein the vector is selected from a group consisting of a cloning vector, a eukaryotic expression vector, a prokaryotic expression vector and a shuttle vector.

6. The pharmaceutical composition of claim 3, wherein the vector is selected from a group consisting of a lentiviral vector and an adenoviral vector.

7. The pharmaceutical composition of claim 4, wherein the host cell is selected from one or more of 239T cell and SHG44 cell.

8. Use of a combination of a recombinant human 2Ig-B7-H3 protein encoding gene with a wild-type 2Ig-B7-H3 protein encoding gene, in the preparation of a medicament for treating cancer, wherein the recombinant human 2Ig-B7-H3 protein encoding gene comprises the nucleotide sequence shown in SEQ ID NO:1 and the wild-type 2Ig-B7-H3 protein encoding gene comprises the nucleotide sequence shown in SEQ ID NO:2, and wherein the cancer is liver cancer or lung cancer.

9. The use of claim 8, wherein the recombinant human 2Ig-B7-H3 protein encoding gene and the wild-type 2Ig-B7-H3 protein encoding gene are carried by a vector, respectively.

10. The use of claim 9, wherein the vector is expressed in a host cell.

11. The use of claim 9, wherein the vector is selected from a group consisting of a cloning vector, a eukaryotic expression vector, a prokaryotic expression vector and a shuttle vector.

12. The use of claim 9, wherein the vector is selected from a group consisting of a lentiviral vector and an adenoviral vector.

13. The use of claim 10, wherein the host cell is selected from one or more of 239T cell and SHG44 cell.